Growing Heart Cells Just for You Date: August 23, 2011 Client: Cellular Dynamics International Summary: Peering through a microscope in Madison, Wisconsin, I watched my heart cells beat in a petri dish. Looking like glowing red shrimp without tails, they pulsated and moved very slowly toward one another. Left for several hours, I was told, these cardiomyocytes would coalesce into blobs trying to form a heart. Flanking me were scientists who had conducted experiments that they hoped would reveal whether my heart cells are healthy, whether they're unusually sensitive to drugs, and whether they get overly stressed when I'm bounding up a flight of stairs.
		Design and Synthesis Strategies of Endocyte's Small Molecule Drug Conjugate (SMDC) Technology to be Presented at the 242nd American Chemical Society (ACS) National Meeting & Exposition Date: April 23, 2011 Client: Endocyte, Inc. Summary: WEST LAFAYETTE, Ind., Aug. 23, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company's proprietary design strategies for the synthesis of SMDCs will be outlined in six poster presentations at the 242nd American Chemical Society (ACS) National Meeting & Exposition, Aug. 28 to Sept. 1, in Denver.
		At-the-market offering for biotech funding? Review 4 quick perspectives Date: August 22, 2011 Client: Brinson Patrick Summary: When it needed to raise $3.7 million for ongoing clinical trials earlier this year, Icagen (NASDAQ:ICGN) chose a road less traveled.
		REITs Hit the ATM for Funds Date: August 22, 2011 Client: Brinson Patrick Summary: When Capstead Mortgage Corp. executives raise money for their real estate investment trust, they either can do it drip by drip or in one huge flood.
		AVI BioPharma Initiates Dosing in Phase 2 Study of Eteplirsen in Duchenne Muscular Dystrophy Patients Date: August 15, 2011 Client: AVI BioPharma, Inc. Summary: AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a Phase 2 study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD).
		Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance, and Chief Financial Officer Date: August 12, 2011 Client: Arena Pharmaceuticals, Inc. Summary: SAN DIEGO, August 12, 2011 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Robert E. Hoffman will rejoin Arena on August 29, 2011, as Vice President, Finance, and Chief Financial Officer. Mr. Hoffman served in various financial positions with Arena for over 13 years before departing in March to work for a private biopharmaceutical company.
		'Luxury' Emergency Center Opening Near World Trade Center Next Month Date: August 11, 2011 Client: Medhattan Summary: LOWER MANHATTAN — A new urgent care center opening soon near the World Trade Center will feel more like a spa than an emergency room.
		Endocyte Reports Second Quarter 2011 Financial Results and Operations Update Date: August 11, 2011 Client: Endocyte, Inc. Summary:WEST LAFAYETTE, Ind., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalized therapy, today announced financial results for the second quarter ending June 30, 2011, and provided an operational update.
		AVI BioPharma to Present Company Overview at the Wedbush Securities Life Science Conference Date: August 10, 2011 Client: AVI BioPharma, Inc. Summary: BOTHELL, WA, Aug 10, 2011 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc., a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the Wedbush Securities Life Science Conference in New York City on Wednesday, August 17, at 9:10 a.m. Eastern Time. Chris Garabedian, AVI's president and CEO, will provide a company overview.
		Endocyte, Inc. to Present at the Wedbush 2011 Life Sciences Management Access Conference Date: August 10, 2011 Client: Endocyte, Inc. Summary: WEST LAFAYETTE, Ind., Aug 10, 2011 (GlobeNewswire via COMTEX) -- Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Ron Ellis, President and CEO of Endocyte, will present at the upcoming 2011 Life Sciences Management Access Conference on Wednesday, August 17, 2011 at 8:00 AM EDT. The conference is being held at Le Parker Meridien in New York.
		MRSA treatment from Cempra inching toward phase 3 trials (price tag:$60M) Date: August 8, 2011 Client: Cempra Pharmaceuticals Summary: The growing prevalence of drug-resistant bacteria means a rise in so-called superbugs with no antibiotics to treat them. Cempra Pharmaceuticals aims to bring new antibacterial weapons to that fight.
		Products, FDA Clarity Draw Pharma Back to Antibiotics Date: August 8, 2011 Client: Cempra Pharmaceuticals Summary: It seems big pharma may be coming back to antibiotics, a treatment area they previously left for dead.
		AVI BioPharma Announces Second Quarter 2011 Financial Results and Recent Corporate Developments Date: August 4, 2011 Client: AVI BioPharma, Inc. Summary: AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and six months ended June 30, 2011, and provided an update of recent corporate developments.
		Endocyte Announces Second Quarter 2011 Earnings Conference Call Date: August 4, 2011 Client: Endocyte, Inc. Summary: WEST LAFAYETTE, Ind., Aug 4, 2011 (GlobeNewswire via COMTEX) -- Endocyte, Inc. ECYT -6.01% , a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, August 11, 2011, at 4:30 PM Eastern Daylight Time to discuss its second quarter 2011 financial results and provide an operational update.
		Use of Alternative Financing Vehicles by Public Companies on the Increase; Topic is Focus of Panel Discussion at Southern California Investor Conference on Aug. 29 Date: August 4, 2011 Client: Binson Patrick Summary: NEW YORK, Aug. 4, 2011 – The increasing use of alternative financing vehicles by public companies will be the focus of a panel discussion at the Southern California Investor Conference on Aug. 29, 2011, at The Island Hotel in Newport Beach.
		Phase 3 ANCHOR and MARINE Trial Data to be Presented in November at the American Heart Association's Scientific Sessions Date: August 4, 2011 Client: Amarin Corporation plc Summary: MYSTIC, Conn. and DUBLIN, Ireland, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that data from each of its two pivotal Phase 3 studies, the ANCHOR trial and the MARINE trial, will be presented at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla. The presentation of the ANCHOR trial results will be the first presentation of data from this trial at a scientific session. The presentation of MARINE trial results will include data that has not been previously presented.
		Endocyte, Inc. to Present at the Canaccord Genuity 31st Annual Growth Conference Date: August 3, 2011 Client: Endocyte, In Summary: West Lafayette, Ind., August 3, 2011 – Endocyte, Inc. (NASDAQ Global Market: ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Mike Sherman, Chief Financial Officer of Endocyte, will present at the upcoming Canaccord Genuity 31st Annual Growth Conference on Tuesday, August 9, 2011 at 4:30 PM EDT in the San Francisco Room. The conference is being held at the InterContinental Boston in Boston, Massachusetts.
		Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses Date: August 2, 2011 Client: Arena Pharmaceuticals, Inc. Summary: SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 2, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin concentrations in human cerebrospinal fluid (CSF) and plasma and related data analyses. The study was conducted to provide additional data that may be informative for determining the human relevance of the observation of brain astrocytoma in male rats. Using the results of this study and other preclinical and clinical studies, Arena estimates that the mean exposure of the human brain to lorcaserin at the clinically tested dose (10 mg dosed twice daily (BID)) is approximately 1.7 times the exposure in the human plasma. In contrast, the measured exposure of the male rat brain to lorcaserin at the dose at which no brain astrocytoma was observed (10 mg/kg/day) is approximately 24 times the exposure in the rat plasma.
		Arena Passes Small Study, in Bid to Answer FDA Questions About Obesity Drug Date: August 2, 2011 Client: Arena Pharmaceuticals, Inc. Summary: San Diego-based Arena Pharmaceuticals faces a lot of questions that need to be answered before it can hope to win FDA clearance to sell its obesity pill. Now the drug developer says it has at least one piece of the puzzle it hopes will satisfy U.S. drug regulators.